Search

Search results

399 results found

Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.

Jemec, G B E, M M Okun, S B Forman, W P F Gulliver, E P Prens, U Mrowietz, A W Armstrong, et al. 2019. “Adalimumab Medium-Term Dosing Strategy in Moderate-to-Severe Hidradenitis Suppurativa: Integrated Results from the Phase III Randomized Placebo-Controlled PIONEER Trials.”. The British Journal of Dermatology 181 (5): 967-75.

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.

Alikhan, Ali, Christopher Sayed, Afsaneh Alavi, Raed Alhusayen, Alain Brassard, Craig Burkhart, Karen Crowell, et al. 2019. “North American Clinical Management Guidelines for Hidradenitis Suppurativa: A Publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, Evaluation, and the Use of Complementary and Procedural Management.”. Journal of the American Academy of Dermatology 81 (1): 76-90.

Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10.

Kimball, Alexa B, Tatsuyoshi Kawamura, Krupali Tejura, Carol Boss, Ana R Hancox, Jonathan C Vogel, Seth M Steinberg, Maria L Turner, and Andrew Blauvelt. 2002. “Clinical and Immunologic Assessment of Patients With Psoriasis in a Randomized, Double-Blind, Placebo-Controlled Trial Using Recombinant Human Interleukin 10.”. Archives of Dermatology 138 (10): 1341-6.